Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
Xue. Xiao-Chang XC; Wu. Yong-Jie YJ; Gao. Ming-Tang MT; Li. Wen-Guang WG; Zhao. Ning N; Wang. Zeng-Lu ZL; Bao. Chun-Jie CJ; Yan. Zhen Z; Zhang. Ying-Qi YQ
Key Findings
- Both intramuscular (IM) and intragastric (IG) BPC‑157 reduced ulcer area in several rat ulcer models.
- IM administration was consistently more effective than IG, achieving up to ~66% inhibition of ulcer formation.
- Effective doses in rats were 400–800 ng/kg; higher doses gave stronger protection and accelerated tissue healing.
- At 800 ng/kg IM, BPC‑157 performed as well as or better than famotidine, a standard ulcer medication.
Practical Outcomes
- For biohackers, this animal work suggests BPC‑157 could be a promising oral or injectable supplement for stomach protection, with injections possibly offering stronger benefits. The effective rat doses translate to very low microgram amounts for humans, but human dosing and safety are still untested, so any self‑experiment should start at the lowest possible dose and monitor gut health closely.
Summary
In rats, the peptide BPC‑157 (a 15‑amino‑acid fragment) helped prevent and heal stomach ulcers. Giving it by injection into muscle worked better than swallowing it, and doses around 400‑800 ng per kilogram reduced ulcer size by roughly half to two‑thirds, even matching or beating a common ulcer drug (famotidine).
Abstract
To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods. Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers. Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control). Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer. The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.
Study Information
pubmed
2004
2004-04-01T00:00:00.000Z
10.3748/wjg.v10.i7.1032